meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced hepatocellular cancer (mHCC)
mHCC - (neo)adjuvant (NA)
3
mHCC - 1st line (L1)
10
mHCC - 2nd line (L2)
2
lung cancer : non small cell (NSCLC)
5
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus bevacizumab
sintilimab based treatment
sintilimab
Immune checkpoint association
nivolumab plus ipilimumab
versus all
vs chemotherapy
vs Standard of Care (SoC)
vs immune chekpoint inhibitors
vs anti-PD-(L)1
vs nivolumab based treatment
vs nivolumab alone
All patients
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
Statistically conclusive or suggested result
Inconclusive results
Uncertain results
Safety results
mHCC - (neo)adjuvant (NA)
metastatic/advanced hepatocellular cancer (mHCC)
mHCC - (neo)adjuvant (NA)
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open